Research location
Gidle
Poland
Advertisement
Research activity in Gidle
PolandCureCurrent currently publishes aggregate city-level research activity for this location: 8 trials and 8 site observations.
The map is centered on registry-derived city coordinates. Circle size reflects published trial activity.
Below are current trials with one or more ClinicalTrials.gov site observations in this city. Results are paginated 50 per page, with recruiting studies shown first.
Trials with sites in Gidle
8 linked trials · page 1 of 1A 24-week Evaluation of GSK573719/Vilanterol (62.5/25mcg) and Components in COPDNCT01313650 · 2011-03-01 · 1 site observation
COMPLETED
24-week Trial Comparing GSK573719/GW642444 With GW642444 and With Tiotropium in Chronic Obstructive Pulmonary DiseaseNCT01316900 · 2011-03-01 · 1 site observation
COMPLETED
Safety Study of the Effects of Inhaled Fluticasone Furoate/GW642444 on the Hypothalamic-Pituitary-Adrenal (HPA) AxisNCT01086410 · 2010-03-01 · 1 site observation
COMPLETED
28-day Repeat Dose Study of GSK573719NCT01030965 · 2009-12-15 · 1 site observation
COMPLETED
Efficacy and Safety Study of Fluticasone Furoate (FF)/GW642444 Inhalation Powder and the Individual Components in Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT01054885 · 2009-10-19 · 1 site observation
COMPLETED
Efficacy and Safety Study of GSK679586 in Patients With Severe AsthmaNCT00843193 · 2008-12-09 · 1 site observation
COMPLETED
A Study To Assess Efficacy And Safety Of Different Doses Of GW642444 In Subjects With Chronic Obstructive Pulmonary Disease (COPD)NCT00606684 · 2008-02-01 · 1 site observation
COMPLETED
A Comparison of Symbicort® pMDI 2 x 160/4.5 μg Bid and Symbicort® pMDI 2 x 80/4.5 μg Bid With Formoterol Turbuhaler®, Budesonide pMDI, the Combination of Formoterol Turbuhaler® and Budesonide pMDI, and Placebo in COPD PatientsNCT00206154 · 2005-04-01 · 1 site observation
COMPLETED
Advertisement
Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.